Novo vs Lilly: How the Obesity-Drug Leader Lost its Lead

Novo Nordisk once dominated the obesity-drug race and briefly stood as Europe’s most valuable listed company. That lead has vanished.

Shares have plunged more than 70 percent from their peak while Eli Lilly’s stock has surged. Lilly’s Zepbound is on track to outsell Wegovy by more than USD 7 billion this year.

Investors and analysts now press CEO Mike Doustdar for a clear strategy beyond semaglutide as patent cliffs approach in the early 2030s and the late-stage pipeline thins.

 The central question is whether Novo can rebuild growth outside its blockbuster weight-loss franchise before competition and patent expiry lock in permanent disadvantage.

The Pipeline Setback That Deepened Doubts

Novo halted trials of its experimental heart drug ziltivekimab, delivering a fresh blow to long-term sales expectations. The setback followed an earlier trial disappointment with next-generation obesity candidate CagriSema in February.

Key pressure points include:

• Semaglutide patent protection expires in the early 2030s
• Late-stage pipeline remains sparse ahead of critical readouts next year
• Wegovy oral tablet provides only temporary relief against Lilly’s advancing options

Analysts note that internal research alone cannot close the looming revenue gap.  They urge Novo to prioritize promising early-pipeline candidate zenagamtide over further heavy investment in CagriSema.

Also Read: 10 GLP-1 Drugs Revolutionizing Diabetes & Obesity Treatment

How the Shift Reshapes the Weight-Loss Drug Segment

Novo Nordisk’s setbacks and the rapid rise of Eli Lilly are already altering the competitive dynamics of the weight-loss drug market. Lilly’s Zepbound is on course to outsell Wegovy by more than USD 7 billion this year, ending Novo’s earlier dominance.

The obesity market itself is projected to reach USD 100 billion or more by the early 2030s, yet leadership is no longer guaranteed by a single blockbuster molecule.

Key changes now visible in the segment include:

• First-mover advantage is fading. Novo’s early lead with Wegovy has eroded as Lilly scales faster and delivers stronger commercial momentum.
• Next-generation candidates face higher scrutiny. The February trial setback for CagriSema and the halt of ziltivekimab trials show that incremental improvements no longer satisfy investors or physicians.
• Oral formulations offer only temporary relief. Novo’s Wegovy pill currently holds a head start over Lilly’s oral rival, but analysts describe it as a short-term bridge rather than a lasting solution ahead of the semaglutide patent cliff in the early 2030s.
• Pipeline depth becomes the new battleground. With Novo’s late-stage pipeline thin, the market increasingly rewards companies that can field multiple differentiated assets rather than relying on one franchise.

These pressures are forcing a broader re-rating of the entire weight-loss category. Companies that once competed mainly on efficacy and supply are now judged on their ability to sustain growth beyond the first wave of GLP-1 drugs.

What the Company Must Deliver

Doustdar has already tightened costs, culled lagging programs and sought targeted partnerships. Yet the market demands more. Analysts expect clearer signals of bolt-on acquisitions or licensing deals to replenish the pipeline.

Novo raised its 2026 sales and operating-profit growth outlook in August to a range of zero to minus 6 percent at constant exchange rates, an improvement on the previous forecast, but the adjustment has not restored confidence.

The obesity market itself may exceed USD 100 billion by the early 2030s. Novo still holds a short-term edge with its Wegovy pill over Lilly’s oral rival. That advantage, however, offers only a bridge. Without rapid expansion into new therapeutic areas and a stronger late-stage portfolio, the former obesity drug leader risks watching its lead erode permanently.